Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierOur mission is to accelerate the mastery of biology to advance human health. We are a life sciences technology company focused on building innovative products and solutions to interrogate, understand and master biology. Our integrated research solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. We have built deep expertise across diverse disciplines including chemistry, biology, hardware and software.
In the company’s own words · 10-K filed Feb 13, 2026 · SEC EDGAR
Business segments
Jun 2026 · $158.7MThe company’s own SEC segment disclosure.
- Chromium Consumables$88.5M56%
- Spatial Consumables$42.3M27%
- Service$10.7M7%
- Instruments$7.7M5%
- Spatial Instruments$4.6M3%
- Chromium Instruments$3.1M2%
- Other (1)$1.9M1%
10x Genomics, Inc. (TXG) reported revenue of $151M in Q1 2026 (quarter ended Mar 31, 2026), down 2.6% from the same quarter a year earlier. That came with a gross margin of 70% and net loss of $13M. For the full year FY2025, revenue was $643M (+5.2% year on year) and net income −$44M. Its largest product in Jun 2026 was Chromium Consumables at $88M, 56% of the disclosed total, well ahead of Spatial Consumables at 27%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.
Health Information Services
Ranks #1 of 13 by Smart Score